Bernd Seizinger is chair of Oxford BioTherapeutics

Company
Oxford BioTherapeutics Ltd
Appointee name
Bernd Seizinger
Country

United Kingdom

Oxford BioTherapeutics Ltd, whose lead programme is a monoclonal antibody for acute myeloid leukemia, has appointed Bernd Seizinger as chairman of the board and Jean-Pierre Bizzari as a non-executive director. Dr Seizinger has worked for companies on both sides of the Atlantic Ocean, including as leader of oncology drug discovery at Bristol-Myers Squibb Co and as chief executive and president of the former GPC Biotech AG. Dr Bizzari was head of clinical oncology at Celgene Corp until 2015, and before that he was at Sanofi Aventis. Both executives are medical doctors.

Oxford BioTherapeutics announced the appointment on 9 February 2017.

Copyright 2017 Evernow Publishing Ltd